TIDMCOS

Collagen Solutions PLC

25 July 2017

Hardman Research: Transitioning to sustainable growth

Transitioning to accelerated sustainable growth - Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced recently to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Recent results have highlighted the progress that has been made, and 2018 looks set to benefit from the launch of its first proprietary finished device, ChondroMimetic.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/cos---2017-results---25-july-2017.pdf

 
 To contact us:          Contacts:            mh@hardmanandco.com 
  Hardman & Co            Dr Martin Hall       dmh@hardmanandco.com 
  35 New Broad Street     Dr Dorothea Hill     gp@hardmanandco.com 
  London                  Dr Gregoire Pave 
  EC2M 1NH                +44 20 7194 7622 
  www.hardmanandco.com 
  Follow us on Twitter 
  @HardmanandCo

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABIGDRXBDBGRS

(END) Dow Jones Newswires

July 25, 2017 02:15 ET (06:15 GMT)

Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Healthcare Inv Charts.
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Healthcare Inv Charts.